Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928800 | 0.85 | IDO1 (0.45) | IDO1LMNASMN1; SMN2HTTROCK2 | |
| SCHEMBL1927722 | 0.83 | PTGS1 (0.35) | MEN1KMT2A | |
| SCHEMBL1928930 | 0.83 | IDO1 (0.49) | IDO1LMNASMN1; SMN2HTTROCK2 | |
| SCHEMBL1926529 | 0.83 | TRPV1 (0.38) | KMT2A | |
| SCHEMBL2341181 | 0.83 | GAA (0.38) | LMNAMEN1KMT2A | |
| SCHEMBL1928234 | 0.81 | TRPV1 (0.41) | — | |
| SCHEMBL4317345 | 0.80 | CNR2 (0.38) | LMNAROCK2MEN1KMT2A | |
| SCHEMBL1928085 | 0.80 | HRH4 (0.39) | ROCK2 | |
| SCHEMBL1926400 | 0.79 | IDO1 (0.44) | IDO1LMNASMN1; SMN2HTTROCK2 | |
| SCHEMBL8320312 | 0.77 | TGM2 (0.52) | IDO1LMNASMN1; SMN2HTTTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379514-B1 | 5-MEMBERED HETEROCYCLES, PREPARATION AND APPLICATION THEREOF AS MEDICAMENTS | IPSEN PHARMA (FR) | 2009-07-15 | — | — | EP | claimed |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | LASSAUNIERE PIERRE-ETIENNE CHA | 2008-06-19 | — | — | US | claimed |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-02-17 | — | — | US | claimed |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-08 | — | — | US | claimed |
| US-8288560-B2 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | IPSEN PHARMA S.A.S. (FR) | 2011-07-14 | — | — | US | disclosed |
| US-7956075-B2 | Thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives, e.g., butyl 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate inhibit lipidic peroxidation and monoamine oxidase and modulate sodium channels and are used for treating neurodegenerative disorders or pain. | IPSEN PHARMA S.A.S. (FR) | 2011-06-07 | — | — | US | disclosed |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | LASSAUNIERE PIERRE-ETIENNE CHA | 2008-06-19 | — | — | US | disclosed |
| US-7291641-B2 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-11-06 | — | — | US | disclosed |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-02-17 | — | — | US | disclosed |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, OPRK1 | IDO1 1766/4885LMNA 4096/4885SMN1; SMN2 687/4885 |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OPRK1, HCN1, P2RX7 | IDO1 987/4885LMNA 3964/4885SMN1; SMN2 654/4885 |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | OXER1, OPRL1, CHRNA7 | IDO1 1366/4885LMNA 4025/4885SMN1; SMN2 942/4885 |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, P2RX7 | IDO1 1527/4885LMNA 4299/4885SMN1; SMN2 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.